Catalyst Pharmaceuticals, Inc., (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered in Coral Gables, FL., and was recognized on the Forbes 2024 list as one of America's most successful small-cap companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
View our Privacy Policy: https://catalystpharma.com/privacy-policy/
View our Social Media Guidelines: https://catalystpharma.com/social-media-guidelines/
GENESIS Pharma is a European biopharmaceutical company specializing in the commercialization of innovative pharmaceutical products for serious and rare diseases.
Established in 1997, GENESIS Pharma was the first pharmaceutical company in Greece and one of the first in Europe to focus on the sales, marketing and distribution of biopharmaceutical products. Shortly after its founding, the company began to steadily expand at a regional level, currently covering 24 countries in Europe.
The robust network of its strategic partnerships comprises leading international pharmaceutical companies dedicated to cutting-edge R&D, alongside fast-growing biopharmaceutical companies with pioneering research and disruptive innovations in the development of targeted, specialized treatments for orphan diseases. In total, GENESIS Pharma holds a product portfolio covering over 30 serious and rare diseases.